Jazz Pharmaceuticals plc (J7Z) — Net Asset Quality Index
Jazz Pharmaceuticals plc (J7Z) has a Net Asset Quality Index of 38.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €11.86 Billion minus total liabilities of €7.33 Billion yields net assets of €4.53 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Jazz Pharmaceuticals plc debt and liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Jazz Pharmaceuticals plc Net Asset Quality Index Over Time (2013–2025)
This chart shows how Jazz Pharmaceuticals plc's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 38.2%, representing net assets of €4.53 Billion against total assets of €11.86 Billion EUR. For live market cap and overall valuation, see Jazz Pharmaceuticals plc (J7Z) market capitalisation.
Annual Net Asset Quality Index for Jazz Pharmaceuticals plc (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Jazz Pharmaceuticals plc from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check J7Z PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 37.0% | €4.32 Billion | €11.66 Billion | €7.34 Billion | ▲ +3.0 pp |
| 2024 | 34.1% | €4.09 Billion | €12.01 Billion | €7.92 Billion | ▲ +1.3 pp |
| 2023 | 32.8% | €3.74 Billion | €11.39 Billion | €7.66 Billion | ▲ +4.3 pp |
| 2022 | 28.5% | €3.09 Billion | €10.84 Billion | €7.75 Billion | ▼ -3.8 pp |
| 2021 | 32.2% | €3.97 Billion | €12.30 Billion | €8.33 Billion | ▼ -23.8 pp |
| 2020 | 56.0% | €3.66 Billion | €6.54 Billion | €2.88 Billion | ▼ -0.2 pp |
| 2019 | 56.2% | €3.11 Billion | €5.54 Billion | €2.43 Billion | ▲ +3.2 pp |
| 2018 | 53.0% | €2.76 Billion | €5.20 Billion | €2.45 Billion | ▲ +0.0 pp |
| 2017 | 53.0% | €2.71 Billion | €5.12 Billion | €2.41 Billion | ▲ +13.8 pp |
| 2016 | 39.1% | €1.88 Billion | €4.80 Billion | €2.92 Billion | ▼ -8.9 pp |
| 2015 | 48.0% | €1.60 Billion | €3.33 Billion | €1.73 Billion | ▲ +6.9 pp |
| 2014 | 41.1% | €1.37 Billion | €3.34 Billion | €1.97 Billion | ▼ -16.8 pp |
| 2013 | 57.9% | €1.30 Billion | €2.24 Billion | €942.69 Million | — |